Psoriasis | Current Treatment | Physician Insights | EU5 | 2018


Psoriasis Current Treatment: Physician Insights probes the current and future use of topical agents, phototherapy, and systemic therapies in the treatment of mild, moderate, and severe psoriasis in the EU5. It extensively examines the use of approved biologics and Otezla, including patient share, line of therapy, drivers of treatment selection, and barriers to broader uptake. The insights offered are based on primary market research with practicing dermatologists in the EU5.


  • Which patients are being prescribed which treatments?
  • What is the sequencing of treatment for psoriasis?
  • What do physicians report as recent and anticipated changes in their treatment practices?
  • What are the dermatologist-reported factors determining current prescribing patterns and recent/anticipated changes?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Markets covered:France, Germany, Italy, Spain, United Kingdom

Primary research: Survey of 253 dermatologists in the EU5 fielded in March 2018.

Key companies: AbbVie, Amgen, Biogen, Celgene, Celltrion, Eli Lilly, Hospira, Janssen, LEO Pharma, Novartis, Sandoz

Key drugs: Benepali, Cosentyx, Enbrel, Erelzi, Flixabi, Humira, Inflectra, Kyntheum, Otezla, Remicade, Remsima, Taltz, Tremfya

Login to access report